0000000001021027

AUTHOR

Antoine Grigis

MOESM2 of Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

Additional file 2: Appendix S2. Proposed list of instruments used for baseline clinical assessments and longitudinal monitoring of symptoms, medication adherence and lithium response.

research product

MOESM2 of Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

Additional file 2: Appendix S2. Proposed list of instruments used for baseline clinical assessments and longitudinal monitoring of symptoms, medication adherence and lithium response.

research product

MOESM1 of Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

Additional file 1: Appendix S1. Country and location of centres involved in R-LiNK.

research product

Contrastive Learning with Continuous Proxy Meta-data for 3D MRI Classification

Traditional supervised learning with deep neural networks requires a tremendous amount of labelled data to converge to a good solution. For 3D medical images, it is often impractical to build a large homogeneous annotated dataset for a specific pathology. Self-supervised methods offer a new way to learn a representation of the images in an unsupervised manner with a neural network. In particular, contrastive learning has shown great promises by (almost) matching the performance of fully-supervised CNN on vision tasks. Nonetheless, this method does not take advantage of available meta-data, such as participant’s age, viewed as prior knowledge. Here, we propose to leverage continuous proxy me…

research product

Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

Abstract Background Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. Structure The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a …

research product